BLGO on OTC
BIOLARGO, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with CitroTech Inc., GULF RESOURCES, INC. or ASCENT INDUSTRIES CO., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
43.9%Gross margin3
-191.3%Operating margin3
-195.6%Net margin3
-56.3%Revenue growth, 20253
-375.8%Return on equity3
0.51×Debt to equity3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 74% of the revenue BIOLARGO, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $16.8M | $5.8M |
| Service | $1.0M | $2.0M |
Business segments
Odor-No-More brought in 69% of the revenue BIOLARGO, INC. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Odor-No-More | $15.6M | $5.9M |
| BioLargo Engineering, Science & Technologies, LLC | $3.2M | $2.5M |
| BioLargo Canada | $72.0K | $86.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue23¢$4.4M
- Research and development14¢$2.6M
- Selling, general and admin63¢$11.8M
Out of $7.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue from Contract with Customer, Including Assessed Tax | $7.8M | $17.8M |
| Cost of Goods and Services Sold | -$4.4M | -$9.9M |
| Gross profit | $3.4M | $7.9M |
| Selling, general and administrative expenses | $11.8M | $9.3M |
| Research and development | $2.6M | $2.9M |
| Impairment expense | $14.0K | |
| Credit Loss Expense | $3.9M | $0 |
| Total operating expenses | $18.3M | $12.2M |
| Operating loss | -$14.9M | -$4.3M |
| PPP forgiveness | $0 | $97.0K |
| Finance fee | $0 | -$106.0K |
| Grant income | $6.0K | $26.0K |
| Interest income | $200.0K | $38.0K |
| Interest expense | -$540.0K | -$71.0K |
| Total other expense | -$334.0K | -$16.0K |
| Net loss attributable to noncontrolling interest | -$3.4M | -$1.9M |
| Net loss attributable to common stockholders | -$11.8M | -$2.4M |
| Loss per share attributable to stockholders basic and diluted (in dollars per share) | -$0.04 | -$0.01 |
| Weighted average number of common shares outstanding: (in shares) | 307.0M shares | 298.1M shares |
| Net loss | -$15.2M | -$4.3M |
| Foreign currency translation adjustment | -$24.0K | $94.0K |
| Comprehensive loss | -$15.2M | -$4.3M |
| Comprehensive loss attributable to noncontrolling interest | -$3.4M | -$1.9M |
| Comprehensive loss attributable to stockholders | -$11.8M | -$2.3M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.9M | $3.5M | |
| Accounts receivable, net of allowance | $615.0K | $3.2M | |
| Inventories, net of allowance | $310.0K | $330.0K | |
| Prepaid expenses and other current assets | $306.0K | $91.0K | |
| Total current assets | $5.1M | $7.1M | |
| Equipment and leasehold improvements, net | $1.6M | $1.7M | |
| Other non-current assets | $106.0K | $95.0K | |
| Operating lease right-of-use assets, net of amortization | $1.0M | $992.0K | |
| Financing lease right-of-use asset, net of amortization | $338.0K | $451.0K | |
| Investment in South Korean joint venture | $0 | $14.0K | |
| Total assets | $8.3M | $10.5M | |
| Accounts payable and accrued expenses | $1.2M | $946.0K | |
| Contract liability | $280.0K | $0 | |
| Operating lease liability | $210.0K | $105.0K | |
| Finance lease liability | $103.0K | $88.0K | |
| Deposits | $189.0K | $90.0K | |
| Total current liabilities | $5.1M | $2.6M | |
| Operating lease liability, net of current | $864.0K | $922.0K | |
| Finance lease liability, net of current | $257.0K | $360.0K | |
| Total long-term liabilities | $1.7M | $1.8M | |
| Total liabilities | $6.8M | $4.5M | |
| Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 317,377,777 and 301,274,243 Shares Issued, at December 31, 2025 and December 31, 2024 | $213.0K | $202.0K | |
| Additional paid-in capital | $165.3M | $158.3M | |
| Accumulated deficit | -$161.3M | -$149.5M | |
| Accumulated other comprehensive loss | -$207.0K | -$183.0K | |
| Total BioLargo Inc. and subsidiaries stockholders equity | $4.0M | $8.9M | |
| Non-controlling interest (Note 9, 10, 11) | -$2.5M | -$2.8M | |
| Total stockholders equity | $1.5M | $6.1M | $4.2M |
| Total liabilities and stockholders equity | $8.3M | $10.5M | |
| Convertible Preferred Stock, Par Value (in dollars per share) | $0.00 | $0.00 | |
| Convertible Preferred Stock, Shares Authorized (in shares) | 50.0M shares | 50.0M shares | |
| Convertible Preferred Stock, Shares Issued (in shares) | 0 shares | 0 shares | |
| Convertible Preferred Stock, Shares Outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 550.0M shares | 550.0M shares | |
| Common stock, shares issued (in shares) | 317.4M shares | 301.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | -$15.2M | -$4.3M |
| Stock option compensation expense | $3.0M | $2.1M |
| Common stock issued for services | $648.0K | $416.0K |
| Credit loss expense | $3.9M | $13.0K |
| Operating lease right-of-use assets amortization | $148.0K | $100.0K |
| Finance lease right -of-use asset amortization | $113.0K | $0 |
| Operating lease liabilities, net | -$137.0K | -$82.0K |
| Finance lease liability, net | -$88.0K | $0 |
| Interest expense related to amortization of the discount on note payable | $196.0K | $0 |
| Fair value of warrants issued for a fee and interest | $0 | $106.0K |
| Loss on investment in South Korean joint venture | $14.0K | $5.0K |
| PPP forgiveness | $0 | -$97.0K |
| Depreciation expense | $145.0K | $155.0K |
| Accounts receivable | -$1.8M | -$569.0K |
| Inventories | $20.0K | -$177.0K |
| Prepaid expenses and other assets | -$226.0K | -$58.0K |
| Deposits | $99.0K | -$27.0K |
| Contract liabilities | $280.0K | -$303.0K |
| Net cash used in operating activities | -$8.3M | -$3.2M |
| Equipment purchases | -$46.0K | -$1.2M |
| Clyra Medical note receivable | $0 | -$82.0K |
| Repayment of note receivable | $481.0K | $0 |
| Net cash provided by (used in) investing activities | $435.0K | -$1.3M |
| Proceeds from sale of common stock, net of offering costs | $2.0M | $594.0K |
| Proceeds from BioLargo stock option exercise | $0 | $153.0K |
| Proceeds (repayments) from debt obligations, net | $24.0K | -$14.0K |
| Net cash provided by financing activities | $8.2M | $4.4M |
| Net change in cash | $335.0K | $9.0K |
| Net effect of foreign currency translation | -$24.0K | $94.0K |
| Interest | $344.0K | $33.0K |
| Income taxes | $0 | $0 |
| Short-term lease payments not included in lease liability | $51.0K | $49.0K |
| Conversion of accounts receivable to a note receivable | $3.8M | $0 |
| Conversion of debt into shares of BioLargo common stock | $250.0K | $0 |
| Conversion of BETI common sotck to BioLargo common stock | $25.0K | $0 |
| Fair value of warrants issued with Clyra Medical note payable | $231.0K | $160.0K |
| Present value of new Clyra Medical right-of-use asset and operating lease liability | $184.0K | $0 |
| Present value of new financing right of use and lease liability | $0 | $451.0K |
| Allocation of noncontrolling interest | $2.6M | $993.0K |
Former names
Recent filings
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Oct 2, 20264
- Sep 14, 20268-K/A
- Sep 11, 20268-K
- Aug 14, 202610-Q
- Jul 7, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOLARGO, INC. filings on SEC EDGAR
- 2SEC EDGARBIOLARGO, INC. filings on SEC EDGAR
- 3SEC EDGARBIOLARGO, INC. 10-K for fiscal 2025
- 4SEC EDGARBIOLARGO, INC. 10-K for fiscal 2019
- 5SEC EDGARBIOLARGO, INC. 10-K for fiscal 2020
- 6SEC EDGARBIOLARGO, INC. 10-K for fiscal 2021
- 7SEC EDGARBIOLARGO, INC. 10-K for fiscal 2022
- 8SEC EDGARBIOLARGO, INC. 10-K for fiscal 2023
- 9SEC EDGARBIOLARGO, INC. 10-Q for fiscal 2026
- 10SEC EDGARBIOLARGO, INC. 10-Q for fiscal 2026